• Browsing: »
  • Home
  • » Archives

Tag Archive | Ward 86

When AIDS Came to Uganda

When AIDS Came to Uganda

By jasonbardi July 28, 2012

More from Moses Kamya, MB, ChB, MMed, MPH, PhD, a professor and chair of the department of medicine at Makerere University in Kampala Uganda, who talks about AIDS and its effect in Uganda. Here he talks about the first case of AIDS he saw in Uganda, a friend and medical student in his class came […]

PEPFAR from a U.S. Perspective

PEPFAR from a U.S. Perspective

By jasonbardi July 28, 2012

In the last video we looked at the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) from the perspective of a doctor in a recipient country. Here we talk to Ambassador Mark Dybul, who co-directs the Global Health Law Program at Georgetown University Law Center’s O’Neill Institute for National and Global Health Law, where he is also a […]

PEPFAR from a Ugandan Perspective

By jasonbardi July 28, 2012

Winding the blog down, it’s worth taking a look at one of the big themes of this meeting: what works. In the case of HIV/AIDS we know treatment and prevention work and we know that one of the most successful examples of this is the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) Here Moses […]

The Need for Global AIDS Activism

By jasonbardi July 27, 2012

More on activism from retired UCSF professor Art Ammann. Here he discusses the need for global activism to confront HIV/AIDS worldwide. “Why is a person going to change their behavior — why is a government going to change its behavior? They’re not going to rudy the literature and go over things and say, “We’re going […]

Should U.S. women use PrEP? Will they?

Should U.S. women use PrEP? Will they?

By jasonbardi July 27, 2012

Although there have been exciting advances in the field of HIV pre-exposure prophylaxis (PrEP) over the past several years, the implications of PrEP for women have been more murky.  Some major PrEP trials have shown efficacy of this strategy in heterosexual African women, but there have been no clinical trials investigating the utility of PrEP […]

How TB and HIV Drugs Interact (video)

By jasonbardi July 27, 2012

Earlier this week Annie Luetkemeyer presented work questioning new FDA guidelines on treating people infected with both HIV and tuberculosis (TB). Here she describes how HIV and TB drugs interact. Background: In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with […]

Preventing TB and Treating HIV-TB Coinfection

By jasonbardi July 26, 2012

A report by Annie Luetkemeyer, MD, assistant clinical professor of medicine, UCSF Division of HIV/AIDS at San Francisco General Hospital and Trauma Center: TB studies in Late Breaker Track B session: Raltegravir in HIV-TB coinfection (THLBB01) and the additive benefit of Isoniazid preventative therapy (IPT) in addition to ART for TB prevent (THLBB03) Raltegravir may be an […]

New Antiretroviral Drugs: Elvitegravir

By jasonbardi July 26, 2012

A report by Susa Coffey, MD, associate professor, UCSF HIV/AIDS Division at San Francisco General Hospital and Trauma Center; attending physician, 360 Positive Care Center, UCSF; Editor-in-Chief, UCSF Center for HIV Information and HIV InSite: To maximize the benefits of antiretroviral therapy (ART), people with HIV infection must take their ARVs every day of their lives.  For […]

Earlier ART Reduces Clinical Events in Resource-Limited Settings

By jasonbardi July 26, 2012

Another report by George Beatty, MD, MPH, associate clinical professor of medicine, UCSF Positive Health Program at San Francisco General Hospital and Trauma Center: We also heard from the HPTN 052 team, who reported on a longer follow up and extended spectrum of clinical events in this trial of early vs delayed ART.  With data from more […]

Results from SPRING-2 Study Reported Today

By jasonbardi July 26, 2012

A report by George Beatty, MD, MPH, associate clinical professor of medicine, UCSF Positive Health Program at San Francisco General Hospital and Trauma Center: From today’s late-breakers:  Dolutegravir is non-inferior to raltegravir at 48 weeks. Investigators from the SPRING-2 study, which compared raltegravir (twice a day) to the second-generation integrase inhibitor dolutegravir, reported 48 week results in […]

Follow

Get every new post delivered to your Inbox.

Join 7,356 other followers